{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:46:15Z","timestamp":1791913575457,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11427-024-2697-3","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:02:22Z","timestamp":1729303342000},"page":"2575-2586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats"],"prefix":"10.1007","volume":"67","author":[{"given":"Dexin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoutong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongquan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"crossref","first-page":"e2004832117","DOI":"10.1073\/pnas.2004832117","volume":"118","author":"G Alanis-Lobato","year":"2021","unstructured":"Alanis-Lobato, G., Zohren, J., McCarthy, A., Fogarty, N.M.E., Kublkova, N., Hardman, E., Greco, M., Wells, D., Turner, J.M.A., and Niakan, K.K. (2021). Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos. Proc Natl Acad Sci USA 118, e2004832117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2697_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum, M.A., Langman, C., Cochat, P., Lieske, J.C., Moochhala, S.H., Hamamoto, S., Satoh, H., Mourani, C., Ariceta, G., Torres, A., et al. (2023). PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103, 207\u2013217.","journal-title":"Kidney Int"},{"key":"2697_CR3","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","volume":"14","author":"DL Brooks","year":"2023","unstructured":"Brooks, D.L., Carrasco, M.J., Qu, P., Peranteau, W.H., Ahrens-Nicklas, R.C., Musunuru, K., Alameh, M.G., and Wang, X. (2023). Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing. Nat Commun 14, 3451.","journal-title":"Nat Commun"},{"key":"2697_CR4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clinbiochem.2013.11.021","volume":"47","author":"B Cellini","year":"2014","unstructured":"Cellini, B., Montioli, R., Oppici, E., Astegno, A., and Borri Voltattorni, C. (2014). The chaperone role of the pyridoxal 5\u2032-phosphate and its implications for rare diseases involving B6-dependent enzymes. Clin Biochem 47, 158\u2013165.","journal-title":"Clin Biochem"},{"key":"2697_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C.T., Deshpande, P.S., Dever, D.P., Camarena, J., Lemgart, V.T., Cromer, M.K., Vakulskas, C.A., Collingwood, M.A., Zhang, L., Bode, N.M., et al. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25, 249\u2013254.","journal-title":"Nat Med"},{"key":"2697_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.kint.2023.11.029","volume":"105","author":"Z Chen","year":"2024","unstructured":"Chen, Z., Zhang, D., Zheng, R., Yang, L., Huo, Y., Zhang, D., Fang, X., Li, Y., Xu, G., Li, D., et al. (2024). In vivo base editing rescues primary hyperoxaluria type 1 in rats. Kidney Int 105, 496\u2013507.","journal-title":"Kidney Int"},{"key":"2697_CR7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00467-017-3741-1","volume":"32","author":"O Clifford-Mobley","year":"2017","unstructured":"Clifford-Mobley, O., Rumsby, G., Kanodia, S., Didi, M., Holt, R., and Senniappan, S. (2017). Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Pediatr Nephrol 32, 2159\u20132163.","journal-title":"Pediatr Nephrol"},{"key":"2697_CR8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","volume":"27","author":"P Cochat","year":"2012","unstructured":"Cochat, P., Hulton, S.A., Acquaviva, C., Danpure, C.J., Daudon, M., De Marchi, M., Fargue, S., Groothoff, J., Harambat, J., Hoppe, B., et al. (2012). Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27, 1729\u20131736.","journal-title":"Nephrol Dial Transplant"},{"key":"2697_CR9","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","volume":"29","author":"DA Dalwadi","year":"2021","unstructured":"Dalwadi, D.A., Calabria, A., Tiyaboonchai, A., Posey, J., Naugler, W.E., Montini, E., and Grompe, M. (2021). AAV integration in human hepatocytes. Mol Ther 29, 2898\u20132909.","journal-title":"Mol Ther"},{"key":"2697_CR10","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"JY Dong","year":"1996","unstructured":"Dong, J.Y., Fan, P.D., and Frizzell, R.A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7, 2101\u20132112.","journal-title":"Hum Gene Ther"},{"key":"2697_CR11","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.bbadis.2013.04.010","volume":"1832","author":"S Fargue","year":"2013","unstructured":"Fargue, S., Rumsby, G., and Danpure, C.J. (2013). Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta Mol Basis Dis 1832, 1776\u20131783.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2697_CR12","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J.D., Smith, A.R., Patel, M.C., Shaw, L., Youniss, M.R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018). A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22, 2227\u20132235.","journal-title":"Cell Rep"},{"key":"2697_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman, S.L. (2008). Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88, 125\u2013172.","journal-title":"Physiol Rev"},{"key":"2697_CR14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","volume":"51","author":"Y Frishberg","year":"2014","unstructured":"Frishberg, Y., Zeharia, A., Lyakhovetsky, R., Bargal, R., and Belostotsky, R. (2014). Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 51, 526\u2013529.","journal-title":"J Med Genet"},{"key":"2697_CR15","volume-title":"Use of Splicing Reporter Minigene Assay to Evaluate the Effect on Splicing of Unclassified Genetic Variants","author":"P Gaildrat","year":"2010","unstructured":"Gaildrat, P., Killian, A., Martins, A., Tournier, I., Fr\u00e9bourg, T., and Tosi, M. (2010). Use of Splicing Reporter Minigene Assay to Evaluate the Effect on Splicing of Unclassified Genetic Variants. Totowa: Humana Press."},{"key":"2697_CR16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs, S.F., Frishberg, Y., Hulton, S.A., Koren, M.J., O\u2019Riordan, W.D., Cochat, P., Desch\u00eanes, G., Shasha-Lavsky, H., Saland, J.M., van\u2019t Hoff, W.G., et al. (2021). Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384, 1216\u20131226.","journal-title":"N Engl J Med"},{"key":"2697_CR17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I., and Liu, D.R. (2017). Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471.","journal-title":"Nature"},{"key":"2697_CR18","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","volume":"10","author":"KS Hanlon","year":"2019","unstructured":"Hanlon, K.S., Kleinstiver, B.P., Garcia, S.P., Zaborowski, M.P., Volak, A., Spirig, S.E., Muller, A., Sousa, A.A., Tsai, S.Q., Bengtsson, N.E., et al. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun 10, 4439.","journal-title":"Nat Commun"},{"key":"2697_CR19","doi-asserted-by":"crossref","first-page":"10751086","DOI":"10.1007\/s00467-022-05684-1","volume":"38","author":"W Hayes","year":"2023","unstructured":"Hayes, W., Sas, D.J., Magen, D., Shasha-Lavsky, H., Michael, M., Sellier-Leclerc, A.L., Hogan, J., Ngo, T., Sweetser, M.T., Gansner, J.M., et al. (2023). Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 38, 10751086.","journal-title":"Pediatr Nephrol"},{"key":"2697_CR20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R., and Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6, 1078\u20131094.","journal-title":"Nat Rev Mater"},{"key":"2697_CR21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12859-018-2585-4","volume":"19","author":"GH Hwang","year":"2018","unstructured":"Hwang, G.H., Park, J., Lim, K., Kim, S., Yu, J., Yu, E., Kim, S.T., Eils, R., Kim, J.S., and Bae, S. (2018). Web-based design and analysis tools for CRISPR base editing. BMC BioInf 19, 542.","journal-title":"BMC BioInf"},{"key":"2697_CR22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-020-15892-8","volume":"11","author":"T Jiang","year":"2020","unstructured":"Jiang, T., Henderson, J.M., Coote, K., Cheng, Y., Valley, H.C., Zhang, X.O., Wang, Q., Rhym, L.H., Cao, Y., Newby, G.A., et al. (2020). Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nat Commun 11, 1979.","journal-title":"Nat Commun"},{"key":"2697_CR23","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K.A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al. (2021). Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun 12, 7101.","journal-title":"Nat Commun"},{"key":"2697_CR24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A., and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424.","journal-title":"Nature"},{"key":"2697_CR25","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","volume":"26","author":"C Lai","year":"2018","unstructured":"Lai, C., Pursell, N., Gierut, J., Saxena, U., Zhou, W., Dills, M., Diwanji, R., Dutta, C., Koser, M., Nazef, N., et al. (2018). Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperox-aluria. Mol Ther 26, 1983\u20131995.","journal-title":"Mol Ther"},{"key":"2697_CR26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz, M.L., Papathanasiou, S., Doerfler, P.A., Blaine, L.J., Sun, L., Yao, Y., Zhang, C.Z., Weiss, M.J., and Pellman, D. (2021). Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing. Nat Genet 53, 895\u2013905.","journal-title":"Nat Genet"},{"key":"2697_CR27","doi-asserted-by":"crossref","first-page":"F475","DOI":"10.1152\/ajprenal.00514.2020","volume":"320","author":"Y Li","year":"2021","unstructured":"Li, Y., Zheng, R., Xu, G., Huang, Y., Li, Y., Li, D., and Geng, H. (2021). Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene. Am J Physiol Renal Physiol 320, F475\u2013F484.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2697_CR28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","volume":"28","author":"A Liebow","year":"2017","unstructured":"Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B.R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R.P., Erbe, D., et al. (2017). An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol 28, 494\u2013503.","journal-title":"J Am Soc Nephrol"},{"key":"2697_CR29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.omtm.2020.10.007","volume":"19","author":"S L\u00f3pez-Manzaneda","year":"2020","unstructured":"L\u00f3pez-Manzaneda, S., Ojeda-P\u00e9rez, I., Zabaleta, N., Garc\u00eda-Torralba, A., Alberquilla, O., Torres, R., S\u00e1nchez-Dom\u00ednguez, R., Torella, L., Olivier, E., Mountford, J., et al. (2020). In vitro and in vivo genetic disease modeling via NHEJ-precise deletions using CRISPR-Cas9. Mol Ther-Methods Clin Dev 19, 426\u2013437.","journal-title":"Mol Ther-Methods Clin Dev"},{"key":"2697_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F., Mui\u00f1os, F., Sent\u00eds, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020). A compendium of mutational cancer driver genes. Nat Rev Cancer 20, 555\u2013572.","journal-title":"Nat Rev Cancer"},{"key":"2697_CR31","doi-asserted-by":"crossref","first-page":"137146","DOI":"10.1016\/j.omtm.2022.03.006","volume":"25","author":"R Martinez-Turrillas","year":"2022","unstructured":"Martinez-Turrillas, R., Martin-Mallo, A., Rodriguez-Diaz, S., Zapata-Linares, N., Rodriguez-Marquez, P., San Martin-Uriz, P., Vilas-Zornoza, A., Calleja-Cervantes, M.E., Salido, E., Prosper, F., et al. (2022). In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. Mol Ther-Methods Clin Dev 25, 137146.","journal-title":"Mol Ther-Methods Clin Dev"},{"key":"2697_CR32","doi-asserted-by":"crossref","first-page":"e54363","DOI":"10.7554\/eLife.54363","volume":"9","author":"TL McGregor","year":"2020","unstructured":"McGregor, T.L., Hunt, K.A., Yee, E., Mason, D., Nioi, P., Ticau, S., Pelosi, M., Loken, P. R., Finer, S., Lawlor, D.A., et al. (2020). Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. eLife 9, e54363.","journal-title":"eLife"},{"key":"2697_CR33","volume-title":"GeneReviews(\u00ae)","author":"DS Milliner","year":"1993","unstructured":"Milliner, D.S., Harris, P.C., Sas, D.J., Cogal, A.G., and Lieske, J.C. (1993). Primary Hyperoxaluria Type 1. In GeneReviews(\u00ae), M.P. Adam, J. Feldman, G.M. Mirzaa, R. A. Pagon, S.E. Wallace, L.J.H. Bean, K.W. Gripp, and A. Amemiya, eds. (Seattle (WA), University of Washington, Seattle Copyright \u00a9 1993\u20132023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.."},{"key":"2697_CR34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K., Chadwick, A.C., Mizoguchi, T., Garcia, S.P., DeNizio, J.E., Reiss, C.W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434.","journal-title":"Nature"},{"key":"2697_CR35","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S., and Liu, D.R. (2022). Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806\u20132827.","journal-title":"Cell"},{"key":"2697_CR36","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1073\/pnas.0607218103","volume":"103","author":"EC Salido","year":"2006","unstructured":"Salido, E.C., Li, X.M., Lu, Y., Wang, X., Santana, A., Roy-Chowdhury, N., Torres, A., Shapiro, L.J., and Roy-Chowdhury, J. (2006). Alanine-glyoxylate aminotransfer-ase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 103, 18249\u201318254.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2697_CR37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","volume":"24","author":"DJ Sas","year":"2022","unstructured":"Sas, D.J., Magen, D., Hayes, W., Shasha-Lavsky, H., Michael, M., Schulte, I., Sellier-Leclerc, A.L., Lu, J., Seddighzadeh, A., Habtemariam, B., et al. (2022). Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24, 654\u2013662.","journal-title":"Genet Med"},{"key":"2697_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","volume":"4","author":"CQ Song","year":"2020","unstructured":"Song, C.Q., Jiang, T., Richter, M., Rhym, L.H., Koblan, L.W., Zafra, M.P., Schatoff, E. M., Doman, J.L., Cao, Y., Dow, L.E., et al. (2020). Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng 4, 125\u2013130.","journal-title":"Nat Biomed Eng"},{"key":"2697_CR39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","volume":"16","author":"L Torella","year":"2024","unstructured":"Torella, L., Klermund, J., Bilbao-Arribas, M., Tamayo, I., Andrieux, G., Chmielewski, K.O., Vales, A., Olag\u00fce, C., Moreno-Luqui, D., Raimondi, I., et al. (2024). Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Mol Med 16, 112\u2013131.","journal-title":"EMBO Mol Med"},{"key":"2697_CR40","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano, G., Andrieux, G., Klermund, J., Blattner, G., Pennucci, V., el Gaz, M., Monaco, G., Poddar, S., Mussolino, C., Cornu, T.I., et al. (2021). Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136\u20131147.e5.","journal-title":"Cell Stem Cell"},{"key":"2697_CR41","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M., Fagerberg, L., Hallstr\u00f6m, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, \u00c5., Kampf, C., Sj\u00f6stedt, E., Asplund, A., et al. (2015). Tissue-based map of the human proteome. Science 347, 1260419.","journal-title":"Science"},{"key":"2697_CR42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera, H.C., Kuranda, K., and Mingozzi, F. (2020). AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28, 723\u2013746.","journal-title":"Mol Ther"},{"key":"2697_CR43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner, D.L., Amini, L., Wendering, D.J., Burkhardt, L.M., Aky\u00fcz, L., Reinke, P., Volk, H.D., and Schmueck-Henneresse, M. (2019). High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med 25, 242\u2013248.","journal-title":"Nat Med"},{"key":"2697_CR44","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1038\/ncomms4230","volume":"5","author":"Y Yu","year":"2014","unstructured":"Yu, Y., Fuscoe, J.C., Zhao, C., Guo, C., Jia, M., Qing, T., Bannon, D.I., Lancashire, L., Bao, W., Du, T., et al. (2014). A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages. Nat Commun 5, 3230.","journal-title":"Nat Commun"},{"key":"2697_CR45","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","volume":"9","author":"N Zabaleta","year":"2018","unstructured":"Zabaleta, N., Barberia, M., Martin-Higueras, C., Zapata-Linares, N., Betancor, I., Rodriguez, S., Martinez-Turrillas, R., Torella, L., Vales, A., Olag\u00fce, C., et al. (2018). CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat Commun 9, 5454.","journal-title":"Nat Commun"},{"key":"2697_CR46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2215\/CJN.02810315","volume":"11","author":"F Zhao","year":"2016","unstructured":"Zhao, F., Bergstralh, E.J., Mehta, R.A., Vaughan, L.E., Olson, J.B., Seide, B.M., Meek, A. M., Cogal, A.G., Lieske, J.C., and Milliner, D.S. (2016). Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11, 119\u2013126.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2697_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","volume":"141","author":"H Zhao","year":"2020","unstructured":"Zhao, H., Li, Y., He, L., Pu, W., Yu, W., Li, Y., Wu, Y.T., Xu, C., Wei, Y., Ding, Q., et al. (2020). In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation 141, 67\u201379.","journal-title":"Circulation"},{"key":"2697_CR48","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1002\/ctm2.261","volume":"10","author":"R Zheng","year":"2020","unstructured":"Zheng, R., Fang, X., Chen, X., Huang, Y., Xu, G., He, L., Li, Y., Niu, X., Yang, L., Wang, L., et al. (2020a). Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR\/Cas9 system alleviates primary hyperoxaluria type 1. Clin Transl Med 10, e261.","journal-title":"Clin Transl Med"},{"key":"2697_CR49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.kint.2020.04.049","volume":"98","author":"R Zheng","year":"2020","unstructured":"Zheng, R., Li, Y., Wang, L., Fang, X., Zhang, J., He, L., Yang, L., Li, D., and Geng, H. (2020b). CRISPR\/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1. Kidney Int 98, 947\u2013957.","journal-title":"Kidney Int"},{"key":"2697_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24272\/j.issn.2095-8137.2022.495","volume":"44","author":"R Zheng","year":"2023","unstructured":"Zheng, R., Zhang, D.X., Shao, Y.J., Fang, X.L., Yang, L., Huo, Y.N., Li, D.L., and Geng, H.Q. (2023). Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1. Zool Res 44, 1\u201310.","journal-title":"Zool Res"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2697-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:42:25Z","timestamp":1771425745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2697-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2697-3","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of Interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}